Therapies in the Pipeline for Systemic Autoimmune Diseases - European Medical Journal
×

Browse

Therapies in the Pipeline for Systemic Autoimmune Diseases

| Download as | PDF
Authors:
*Juan Felipe Betancur,1 Jose Fernando Molina,2 Gabriel J. Tobón3
Disclosure:

The authors have declared no conflicts of interest.

Received:
10.03.16
Accepted:
10.05.16
Citation
EMJ Rheumatol. ;3[1]:118-127.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Abstract

The current goals in the development of novel therapeutics of systemic autoimmune diseases are to develop agents more effective than conventional therapies as well as to reduce the risk of organ damage. To achieve this goal, large multicentre randomised controlled trials are needed to confirm the efficacy and safety of novel agents. Whether these novel modalities are synergistic to conventional drugs, the optimal dosages, and duration of treatment, need to be explored.

As expected, the development of new molecules for the treatment of autoimmune diseases is constant, and there are different ongoing clinical trials. We review the different molecules in the pipeline, summarised in Tables 1, 2, and 3. We also show the successes, failures, and molecules that require more evidence.

Please view the full content in the PDF above.